Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas

다국어 초록 (Multilingual Abstract)

Background: Recent studies have revealed that the splicing factor neuro-oncological ventral antigen 1 (NOVA1) is enriched in fibroblasts and accumulated T cells of tertiary lymphoid structures. In the present study, we investigated NOVA1 expression in various subtypes of mature and immature T- and natural killer (NK)-cell lymphomas as well as in various B-cell lymphoma subtypes. Methods: NOVA1 immunoexpression was evaluated in hyperplastic palatine tonsils (n = 20), Tand NK-cell lymphomas (n = 177), diffuse large B-cell lymphomas (n = 151), and other types of B cell lymphomas (n = 31). Nuclear staining intensity and percentage of positive tumor cells were graded. NOVA1 mRNA expression was analyzed in various lymphoma cell lines. Results: Tumor cells of T- and NK-cell lymphomas showed higher expression levels of NOVA1 than did normal paracortical T cells, and 56.5% of T- and NK-cell lymphoma cases showed diffuse and strong expression. The NOVA1 expression level varied according to the subtype; it was higher in angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL), and T lymphoblastic leukemia/lymphoma (T-LBL), but it was lower in ALKpositive ALCL. In almost all B-cell lymphomas, NOVA1 expression was very low or negative. NOVA1 mRNA was also expressed in Jurkat, a T-LBL cell line. Conclusions: The present findings suggest that NOVA1 upregulation may be involved in certain subtypes of T- and NK-cell lymphomas, but not in B-cell lymphomas. Upregulated NOVA1 expression seems to be a specific biological feature of activated T cells such as T- and NK-cell lymphomas.

참고문헌 (Reference)

1 Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" IARC Press 2008

2 Falini B, "Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias" 92 : 519-532, 2007

3 Buckley CD, "Stromal cells in chronic inflammation and tertiary lymphoid organ formation" 33 : 715-745, 2015

4 de la Grange P, "Splicing factor and exon profiling across human tissues" 38 : 2825-2838, 2010

5 Ruddle NH, "Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response" 183 : 2205-2212, 2009

6 Oberdoerffer S, "Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL" 321 : 686-691, 2008

7 Yoon SO, "NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal" 7 : 2475-2495, 2016

8 박은향, "Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma" 대한병리학회 49 (49): 382-388, 2015

9 Drayton DL, "Lymphoid organ development: from ontogeny to neogenesis" 7 : 344-353, 2006

10 Henry C, "Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance" 115 : 2420-2429, 2010

11 Kalsotra A, "Functional consequences of developmentally regulated alternative splicing" 12 : 715-729, 2011

12 Kelemen O, "Function of alternative splicing" 514 : 1-30, 2013

13 Kalluri R, "Fibroblasts in cancer" 6 : 392-401, 2006

14 Merkin J, "Evolutionary dynamics of gene and isoform regulation in mammalian tissues" 338 : 1593-1599, 2012

15 Mallinjoud P, "Endothelial, epithelial, and fibroblast cells exhibit specific splicing programs independently of their tissue of origin" 24 : 511-521, 2014

16 Barash Y, "Deciphering the splicing code" 465 : 53-59, 2010

17 O’Rourke JP, "Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities" 28 : 2091-2101, 2008